



**Maidstone and
Tunbridge Wells**
NHS Trust

Ref: FOI/GS/ID 8078

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

28 March 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Urothelial and Colorectal Cancer.

You asked:

Q1. How many urothelial cancer patients have been treated in the past 3 months with the following agents:

- a. Avelumab*
- b. Atezolizumab*
- c. Carboplatin with Gemcitabine*
- d. Carboplatin single or in any other combination*
- e. Cisplatin with Gemcitabine*
- f. Cisplatin single or in any other combination*
- g. Nivolumab*
- h. Pembrolizumab*
- i. Any other regimen including Paclitaxel*
- j. Any other chemotherapy regimen*
- k. Other active systemic anti-cancer therapy*
- l. Palliative care only*

Q2. How many colorectal cancer [CRC] patients have been treated in the past 3 months with the following agents:

- a. Aflibercept*
- b. Bevacizumab*
- c. Capecitabine*
- d. CAPIRI*
- e. CAPOX (XELOX)*
- f. Cetuximab in combination with FOLFIRI*
- g. Cetuximab in combination with FOLFOX*
- h. Cetuximab not in combination with FOLFIRI or FOLFOX*
- i. Irinotecan only*

- j. FOLFIRI
- k. FOLFOX
- l. Fluorouracil (5FU) only
- m. Oxaliplatin only
- n. Panitumumab in combination with FOLFIRI
- o. Panitumumab in combination with FOLFOX
- p. Panitumumab not in combination with FOLFIRI or FOLFOX
- q. Pembrolizumab
- r. Nivolumab
- s. Raltitrexed
- t. Ramucirumab
- u. Regorafenib
- v. Sorafenib
- w. Other active systemic anti-cancer therapy
- x. Palliative care only

Trust response:

- 1.
 - a. 0
 - b. 1
 - c. 3
 - d. 0
 - e. 2
 - f. 0
 - g. 0
 - h. 0
 - i. 0
 - j. 0
 - k. 0
 - l. 3

- 2.
 - a. 0
 - b. 1
 - c. 30
 - d. 11
 - e. 25
 - f. 13
 - g. 1
 - h. 8
 - i. 0
 - j. 27
 - k. 33
 - l. 2
 - m. 0
 - n. 3
 - o. 1
 - p. 4
 - q. 7
 - r. 3

s.	7
t.	0
u.	2
v.	0
w.	15
x.	10